Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.
Tubío-Santamaría N, Jayavelu AK, Schnoeder TM, Eifert T, Hsu CJ, Perner F, Zhang Q, Wenge DV, Hansen FM, Kirkpatrick JM, Jyotsana N, Lane SW, von Eyss B, Deshpande AJ, Kühn MWM, Schwaller J, Cammann C, Seifert U, Ebstein F, Krüger E, Hochhaus A, Heuser M, Ori A, Mann M, Armstrong SA, Heidel FH. Tubío-Santamaría N, et al. Among authors: hochhaus a. Mol Cancer. 2023 Dec 4;22(1):196. doi: 10.1186/s12943-023-01907-7. Mol Cancer. 2023. PMID: 38049829 Free PMC article.
Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma.
Schrenk KG, Weschenfelder W, Spiegel C, Agaimy A, Stöhr R, Hartmann A, Gaßler N, Drescher R, Freesmeyer M, Malouhi A, Bürckenmeyer F, Aschenbach R, Teichgräber U, Kögler C, Vogt M, Hofmann GO, Hochhaus A. Schrenk KG, et al. Among authors: hochhaus a. J Cancer Res Clin Oncol. 2023 Aug;149(9):5493-5496. doi: 10.1007/s00432-022-04496-y. Epub 2022 Dec 5. J Cancer Res Clin Oncol. 2023. PMID: 36469155 Free PMC article.
Nuclear war and physicians' social responsibility.
Gale RP, Hochhaus A. Gale RP, et al. Among authors: hochhaus a. Leukemia. 2023 Nov;37(11):2147-2149. doi: 10.1038/s41375-023-02025-5. Epub 2023 Sep 12. Leukemia. 2023. PMID: 37700088 No abstract available.
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D. Cortes JE, et al. Among authors: hochhaus a. Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02278-8. Online ahead of print. Leukemia. 2024. PMID: 38755421
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN.
Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Saglio G. Cortes JE, et al. Among authors: hochhaus a. Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.283428. Online ahead of print. Haematologica. 2024. PMID: 38695123 Free article.
682 results